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ABSTRACT
Rationale The relationship between clinical and 
biomarker characteristics of asthma and its severity in 
Africa is not well known.
Methods Using the Expert Panel Report 3, we assessed 
for asthma severity and its relationship with key 
phenotypic characteristics in Uganda, Kenya and Ethiopia. 
The characteristics included adult onset asthma, family 
history of asthma, exposures (smoking and biomass), 
comorbidities (HIV, hypertension, obesity, tuberculosis 
(TB), rhinosinusitis, gastro- oesophageal disease (GERD) 
and biomarkers (fractional exhaled nitric oxide (FeNO), 
skin prick test (SPT) and blood eosinophils). We compared 
these characteristics on the basis of severity and fitted 
a multivariable logistic regression model to assess the 
independent association of these characteristics with 
asthma severity.
Results A total of 1671 patients were enrolled, 70.7% 
women, with median age of 40 years. The prevalence 
of intermittent, mild persistent, moderate persistent and 
severe persistent asthma was 2.9%, 19.9%, 42.6% 
and 34.6%, respectively. Only 14% were on inhaled 
corticosteroids (ICS). Patients with severe persistent 
asthma had a higher rate of adult onset asthma, smoking, 
HIV, history of TB, FeNO and absolute eosinophil count 
but lower rates of GERD, rhinosinusitis and SPT positivity. 
In the multivariate model, Ethiopian site and a history of 
GERD remained associated with asthma severity.
Discussion The majority of patients in this cohort 
presented with moderate to severe persistent asthma 
and the use of ICS was very low. Improving access to ICS 
and other inhaled therapies could greatly reduce asthma 
morbidity in Africa.
InTRoDuCTIon
Asthma has been defined by the global initi-
ative for asthma (GINA) as a heterogeneous 
disease usually characterised by chronic 
airway inflammation and accompanied by 
a history of recurrent or persistent respira-
tory symptoms such as wheeze, shortness of 
breath, chest tightness and cough which varies 
over time and in intensity, along with variable 
airflow obstruction.1 The disease is estimated 
to affect 334 million people globally.2 The 
prevalence of asthma in Africa has been esti-
mated as 7.0% and 9.6% in rural and urban 
areas, respectively, and asthma prevalence is 
rapidly increasing as a result of various factors 
such as urbanisation, increasing exposures to 
environmental risk factors and adoption of 
westernised affluent lifestyles.3 4
Phenotypic characterisation of asthma 
is critical to understanding the underlying 
Key messages
 ► What are the characteristics of asthma in an African 
cohort including severity, phenotypes, medication 
exposure and risk factors?
 ► The prevalence of severe and uncontrolled asthma 
was very high in a setting where access to conven-
tional therapies such as inhaled corticosteroids is 
significantly limited.
 ► In this study, we successfully performed phenotypic 
characterisation of asthma in an African cohort that 
included both clinical factors and biomarkers. This is 
the first report of asthma severity and phenotypes 
in an East African cohort and this manuscript pro-
vides valuable insights into the prevalence of severe 
asthma, the risk factors for poorly controlled disease 
and the inflammatory phenotypes of patients in 
this unique cohort. It highlights the lack of access 
to therapies that have the potential to significantly 
impact asthma outcomes in a meaningful way.
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pathophysiology and aetiology of disease, development of 
more efficacious and targeted therapies, asthma preven-
tion and cure.5 6 It has become increasingly evident that 
tailored therapies are important when managing asthma 
and that accurately identifying inflammatory and clinical 
characteristics is essential when determining the most 
appropriate therapies for patients with asthma of any 
severity.7 8 This paradigm shift in our approach to the 
management of asthma patients is highlighted by the latest 
changes in the GINA strategy that recommend pheno-
typic characterisation of all asthma patients coupled with 
identification and management of comorbid disease and 
risk factor modification.8 Targeting inflammatory pheno-
types results in improvements in asthma outcomes.6 
Despite the known advantages of asthma characterisa-
tion, very little is known about common asthma charac-
teristics and inflammatory phenotypes in Africa.
Asthma severity has been found to be related to several 
phenotypic characteristics such as obesity, age, gender, 
smoking, type of airway inflammation and medication 
use.9–11 As part of the African Severe Asthma Project 
(ASAP) that was conducted in three African countries 
(Ethiopia, Kenya and Uganda), we collected exten-
sive data including socio- demographic, environmental 
and clinical factors (exacerbation rates and healthcare 
resource utilisation), physiological measures, inflamma-
tory biomarkers and markers of allergic sensitisation in 
asthma patients presenting to selected chest clinics in the 
participating countries. The objective of the current anal-
ysis was to determine the overall prevalence rates of the 
studied phenotypic characteristics and asthma severity 
and to determine the association of the studied charac-
teristics with asthma severity in an African cohort.
MeThoDS
Study design
We performed a cross- sectional analysis of baseline data 
collected as part of the ASAP. The ASAP project is a 
prospective, multicentre, cohort study designed to inves-
tigate the prevalence, clinical and phenotypic character-
istics of severe asthma in Africa. The study sites consisted 
of three teaching and national referral hospitals in Ethi-
opia (Black Lion Hospital), Kenya (Kenyatta Hospital) 
and Uganda (Mulago Hospital).
Extensive socio- demographic, environmental, clinical 
and physiological characteristic data and inflammatory 
markers and healthcare resource utilisation rates were 
collected in this unique cohort. The cohort was comprised 
of both participants with a pre- existing diagnosis of 
asthma and those with high- risk symptoms consistent with 
a high likelihood of asthma who presented to selected 
chest clinics in the participating countries. Patients with 
chronic respiratory symptoms such as cough, wheezing, 
chest pain and shortness of breath who presented to 
the hospitals were screened for asthma by study medical 
officers using an asthma screening form (supplemental 
material, Bruce Kirenga ASAP screening form). Positive 
asthma at screening was defined as having at least one of 
the following: (1) >1 characteristic respiratory symptom 
(wheezing, breathlessness, chest tightness and/or cough), 
(2) physician- diagnosed asthma, (3) asthma medica-
tion use with improvement in symptoms, (4) wheezing 
in the previous 12 months and (5) pre- bronchodilator 
(pre- BD) forced expiratory volume (FEV1)/forced vital 
capacity (FVC) ratio <0.70, FEV1 reversibility >12% and 
200 mL. A pulmonologist confirmed the diagnosis in all 
patients who screened positive on the asthma form. Addi-
tional inclusion criteria included age between 12 and 70 
years. We excluded patients with (1) known diagnoses 
of alternative lung disease such as chronic obstructive 
pulmonary disease, bronchiectasis, pulmonary fibrosis 
or tuberculosis (TB), (2) exposure to experimental 
treatments within the past 3 months and (3) pregnancy 
by self- reported last menstrual period. Patients with 
fixed airflow obstruction on spirometry defined as post- 
bronchodilator (post- BD) FEV1/FVC ratio <0.70 were 
also excluded. We estimated that a sample size of 1676 
patients would provide 90% information to determine 
the predictors of severe asthma in the cohort. Eligible 
patients providing informed consent were consecutively 
enrolled between August 2016 and May 2018 until the 
desired sample size was attained.
Study assessments
We collected baseline information including socio- 
demographic characteristics, asthma symptom ques-
tionnaires, physical examination findings, identified 
exposures to both outdoor and indoor asthma triggers, 
smoking history, measured psychosocial stress using ques-
tionnaires and noted the presence of comorbidities (eg, 
allergies and reflux disease). Asthma control was assessed 
using the asthma control questionnaire (ACQ),12 while 
the National Asthma Education and Prevention Program/
National Heart, Lung and Blood Institute Expert Panel 
Report (EPR 3) guideline13 was used for severity grading. 
The EPR 3 guideline divides asthma into intermittent 
and persistent with mild, moderate and severe persistent 
categories. The EPR 3 guideline also recommends that 
asthma severity assessments should only be performed on 
patients who are not currently on asthma therapy.
Spirometry was performed according to American 
Thoracic Society/European Respiratory Society (ATS/
ERS) guidelines14 using a Pneumotrac spirometer with 
Spirotrac V software (Vitalograph Ltd., Buckingham, 
United Kingdom). To achieve uniformity, we used the 
National Health and Nutrition Examination Survey refer-
ences values for the per cent predicted (%pred) FEV1 at 
1 s and the %pred FVC, as no appropriate African refer-
ence values were available at the time of the assessment.15 
Pre- BD spirometry was performed on all patients, and 
post- BD spirometry was repeated 15 min after four doses 
of inhaled salbutamol (400 µg) was administered (each 
dose was separated by 1 min) only in patients with FEV1/
FVC ratio <0.70.
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Skin prick test (SPT) was performed and interpreted 
following a standard operating procedure developed 
based on published international guidelines.16 17 Briefly 
after obtaining consent from the patient, setting an 
emergency tray, confirming the stability and expiry date 
of the allergens, cleaning the skin with 70% alcohol, 
marking sites of application with a skin pen at 2 cm inter-
vals, we applied one drop of each allergen beside the 
marks starting from the palm side and working toward 
the elbow side starting with saline (negative control) and 
ending with histamine (positive control). Using a sterile 
lancet, we pierced the skin through the drop. A new 
lancet was used for each allergen and controls. Reading 
reactions commenced after 15 min. The size of the weal 
was measured at the widest diameter and the diameter 
perpendicular to the widest diameter. An average weal 
diameter ≥3 mm indicated a positive reaction. The aller-
gens used in the study were preselected based on their 
published occurrence in African settings and included 
house dust mite mix, soya bean, Blomia tropicalis, Bermuda 
grass (Cynodon dactylon), mould mix IV, Aspergillus fumi-
gatus, dog epithelia (Canis family), cat epithelia (Felis 
domesticus), German cockroach (Blattella germanica), egg 
white, cow milk, peanut (Arachys hypogaea).18 Allergens 
were specifically prepared for the project by Immuno-
spec (Pty) Ltd.19
Fractional exhaled nitric oxide (FeNO) testing was 
performed with the NO breath FeNO Monitor according 
to manufacturer instructions.20
Clinical laboratories tests including a complete blood 
count were performed to determine the levels of circu-
lating peripheral blood eosinophils, with a five- part 
auto- loader haematology analyser.21 Stool- concentrated 
microscopy was done to look for cysts, ova and parasites, 
while HIV testing was performed according to partici-
pating countries’ ministry of health algorithms for HIV 
testing. Evaluations for ova, parasites and HIV were 
performed due to a concern that the presence of one of 
these common diseases could result in peripheral eosin-
ophilia, thus confounding one of our key inflammatory 
factors of interest.
Definitions
Adult onset asthma was defined as having a self- reported 
diagnosis of asthma at ≥19 years of age.22 Family history of 
asthma, smoking status, biomass exposure, history of TB, 
gastro- oesophageal disease (GERD) and rhinosinusitis 
were all self- reported. HIV testing was performed and the 
presence of a positive test was based on the presence of 
viral antigens on confirmatory testing. Hypertension was 
defined as a blood pressure ≥120/90 mm Hg. High eosin-
ophils were defined as having an absolute eosinophil 
count (AEC) ≥300 cells/µL, high FeNO was defined as 
FeNO ≥35 ppb and allergic status was defined as having at 
least one positive allergen on SPT. Uncontrolled asthma 
was defined as ACQ score >1.512 and asthma exacerba-
tions were defined as an increase in asthma symptoms 
requiring an unscheduled visit to a health facility or 
emergency room or resulting in a hospitalisation (ie, due 
to moderate to severe exacerbations) as recommended 
by the ATS/ERS guidelines.23 24
Statistical analysis
Descriptive statistics are used to summarise enrolled 
patient characteristics. Categorical variables are 
presented as frequencies and percentages for non- 
missing data. Continuous variables are reported as the 
median with IQR 25th and 75th percentiles. The char-
acteristics of interest were compared between severity 
grades using χ2 and Kruskal–Wallis tests for proportions 
and medians, respectively. Asthma severity was dichoto-
mised in intermittent–mild persistent and moderate–se-
vere persistent asthma. A multivariate logistic model 
was fitted to determine independent association of the 
characteristics with moderate–severe persistent asthma. 
Akaike information criteria was used for model selection. 
Predictors that showed multicollinearity using variance 
inflation factor >10 were centred in case of continuous 
variables or dropped from the final model if they were 
categorical and non- significant. Variables of scientific 
importance were retained in the final model even if they 
were not significant. Results are presented using the OR 
with 95% CI. All analyses were done using STATA V.14 
software (Stata Corp.). A p value <0.05 was considered 
statistically significant unless otherwise specified.
ethical considerations
All patients provided informed consent. Patients <18 
years of age provided assent while their parents/legal 
guardians consented.
Patient public involvement
Neither patients nor the public were involved in the 
design and conduct of this study.
ReSulTS
Study patients characteristics
A total of 2242 patients were screened, and 1671 asthma 
patients were enrolled from August 2016 to May 2018 at 
the three sites including 419 in Ethiopia, 431 in Kenya 
and 821 in Uganda. There were 571 excluded patients. 
The reasons for exclusion included not having asthma 
(267), contraindication to spirometry (45), declined to 
give consent (211), age out of range (18) and in experi-
mental treatment trials (17). Overall, the majority of the 
patients (70.7%) were women with a median age of 40 
(26–52) years and median body mass index of 24.2 (20.9–
28.5) kg/m2 (table 1). The median age at asthma onset 
was 25 (14–36) years including 19.3% developing asthma 
at ≤12 years, 16.0% at 12–19 years and 64.7% at >20 years 
of age. Family history of asthma was reported by 52.0%, 
smoking by 6.8% and biomass smoke exposure by 73.0% 
of patients (table 1).
G
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Gender: male, n (%) 490 (29.3) 206 (25.1) 109 (25.3) 175 (41.8)
Median age (IQR) 40 (26–52) 31 (20–44) 42 (32–51) 52 (42–60)
Median age at asthma 
diagnosis (IQR)
25 (14–36) 20 (10–33) 28.5 (16–39) 29 (22–36)
Adult onset asthma (≥19 
years)
1050 (62.8) 421 (51.3) 283 (65.66) 346 (82.6)
Family history of asthma, n 
(%)
869 (52.0) 491 (59.8) 229 (53.1) 149 (35.6)
Smoking (current/former), n 
(%)
113 (6.8) 39 (4.8) 38 (8.8) 36 (8.6)
Secondhand smoke exposure, 
n (%)
141 (8.4) 51 (6.2) 67 (15.6) 23 (5.5)
Biomass exposure, n (%) 1221 (73.1) 643 (78.3) 274 (63.6) 304 (72.6)
Cough, n (%) 736 (44.1) 360 (43.9) 187 (43.4) 189 (45.1)
Wheeze, n (%) 664 (39.7) 319 (38.9) 187 (43.4) 158 (37.7)
Median BMI kg/m2 (IQR) 24.2 (20.9–28.5) 23.7 (20.4–28.4) 26.1 (22.1–30.7) 23.8 (21.1–26.8)
Pre- BD FVC%, median (IQR) 94 (76–109) 101 (84–115) 89 (74–101) 2.3 (1.7–2.9)
Pre- BD FEV1%, median (IQR) 76 (53–95) 87 (65–103) 76 (58–90) 53 (40–69)
Pre- BD FEV1/FVC ratio, 
median (IQR)
0.7 (0.6–0.8) 0.8 (0.7–0.8) 0.7 (0.6–0.8) 0.5 (0.4–0.6)
Bronchodilator reversibility, 
median (IQR)
19 (12–30.8) n=1077 20.5 (15.0–31.6) n=268 9 (4–19) n=408 24.9 (17.3–41.9) n=401
Ova/cysts 1 (0.2) 1 (0.2) 0 (0.0) 0 (0.0)
Uncontrolled asthma (ACQ 
>1.5)
957 (57.3) 427 (52.0) 223 (51.7) 307 (73.3)
Number of exacerbations in 
past year, median (IQR)
3 (1–10) 4 (2–10) 3 (0–10) 2 (0–8)
Number of courses of oral 
steroids prescribed
1 (0–4) 1 (0–4) 0 (0–2) 1 (0–5)
Three or more exacerbations 
in the past year, n (%)
984 (59.1) 566 (68.9) 223 (52.0) 195 (47.0)
Any hospitalisation in past 
year, n (%)
358 (21.4) 204 (24.9) 51 (11.9) 103 (24.6)
On any ICS 230 (14.0) 65 (17.3) 89 (12.7) 76 (13.3)
Not on any asthma medication 206 (12.5) 73 (19.5) 87 (12.6) 46 (8.1)
ACQ, asthma control questionnaire; BMI, body mass index; FEV, forced expiratory volume; FVC, forced vital capacity; ICS, inhaled 
corticosteroids; pre- BD, pre- bronchodilator.
Respiratory symptoms, asthma control, exacerbations, lung 
function and medication utilisation
Forty- four per cent of the patients reported a cough, 
while 39.7% reported history of a wheeze. The median 
number of exacerbations in the year prior to enrolment 
was 3 (IQR: 1–10). Fifty- nine per cent of the population 
experienced ≥3 exacerbations and 21.4% had had at 
least one hospitalisation due to asthma in the year before 
enrolment. Of note, 57.3% of the population had uncon-
trolled asthma as defined by an ACQ score >1.5. The 
median pre- BD %pred FVC was 94 (76–109)%, median 
%pred FEV1 was 76 (53–95)% and the FEV1/FVC ratio 
was 0.70 (0.6–0.8). Only patients with an FEV1/FVC ratio 
had reversibility testing performed and we identified a 
median FEV1 per cent reversibility of 19.0 (12–30.8)% 
(table 1). Rhinosinusitis, obesity and GERD were the 
most prevalent comorbid conditions (table 2).
Medications patients were using at the time of enrol-
ment are shown in table 3. Twenty- four per cent of the 
enrolled patients were on salbutamol tablets, 17.1% 
aminophylline tablets, 13.2% aminophylline injections, 
37.3% oral and 11.4% injectable corticosteroids, only 
14.1% were on an inhaled corticosteroid (ICS) with an 
additional 16.5% using combination ICS/long- acting 
G
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  Uganda, n(%) 819 (49.7) 231 (61.6) 411 (58.5) 177 (31.0)
  Kenya, n(%) 424 (25.7) 108 (28.8) 159 (22.6) 157 (27.5)
  Ethiopia, n(%) 406 (24.6) 36 (9.6) 133 (18.9) 237 (41.5)
Adult onset asthma (onset ≥19 years), 
n (%)
1034 (62.7) 202 (53.9) 433 (61.6) 399 (69.9) <0.001
Age in years (median, IQR)
Family history of asthma, n (%) 861 (52.2) 211 (56.3) 366 (52.1) 284 (49.7) 0.131
Smoking (current/former), n (%) 111 (6.7) 16 (4.3) 37 (5.3) 58 (10.2) <0.001
Biomass smoke, n (%) 1205 (73.1) 271 (72.3) 527 (75.0) 407 (71.3) 0.324
Comorbidities, n (%)
  HIV 63 (3.8) 13 (3.5) 18 (2.6) 32 (5.6) 0.017
  Hypertension 193 (11.7) 34 (9.1) 80 (11.4) 79 (13.8) 0.078
  Obesity 316 (19.2) 70 (18.7) 138 (19.6) 108 (18.9) 0.945
  Tuberculosis 19 (1.2) 5 (1.3) 3 (0.4) 11 (1.9) 0.032
  GERD 288 (17.5) 58 (15.5) 143 (20.3) 87 (15.2) 0.030
  Rhinosinusitis 370 (22.4) 103 (27.5) 174 (24.8) 93 (16.3) <0.001
SPT, N 1649 375 703 571
  At least one positive SPT, % 67.3 69.9 69.3 63.1 0.029
  2–3 positive SPT, % 40.7 45.3 43.1 34.7 0.002
FeNO ppb, N 1334 307 583 444
  Median (IQR) 25 (12–48) 22 (9–40) 22 (11–44) 32 (16–57) <0.001
  FeNO ≥35 ppb, % 37.4 31.9 34.5 45.1 <0.001
AEC, N 1511 356 649 506
  Median (IQR) 270 (140–510) 240 (120–415) 270 (140–510) 305 (160–560) 0.001
  AEC>300 cells/μL, % 45.1 38.2 45.0 50.0 0.003
AEC, absolute eosinophil count; FENO, fractional exhaled nitric oxide; GERD, gastro- oesophageal disease; SPT, skin prick test.
beta agonist therapies (table 3). Overall, 12% were not 
taking any medications for asthma. Severe asthma was 
associated with increased salbutamol inhaler and nebu-
liser use, injectable steroid, leukotrienes and theophyl-
line use. The use of oral and injectable steroids was high 
regardless of asthma severity with one- third of all patients 
receiving oral steroids.
Inflammatory biomarkers
The prevalence of an elevated FeNO level >35 ppb was 
37.4% with a median FeNO level of 25 (12–48). The 
median eosinophil count was 270 (140–510) cells/
µL with 45% of patients having an eosinophil count 
>300 cells/µL (table 2). Two- thirds of the cohort demon-
strated allergic sensitisation with at least one positive 
allergen on SPT. Individual allergen reactivity by country 
is presented in online supplementary table 1. We exam-
ined the prevalence of overlapping inflammatory 
biomarkers and noted that 16.3% of the population had 
three overlapping markers. Of note, 16.4% of the cohort 
had overlapping eosinophils and one positive SPT and 
11.1% had both positive SPT and high FeNO. Lastly, 5% 
of the cohort had overlapping high FeNO and eosino-
phils (figure 1). Interestingly, only 8.9% of patients had 
no positive inflammatory markers.
Asthma severity and selected phenotypic characteristics
The prevalence of mild intermittent, mild, moderate and 
severe persistent asthma was 2.9%, 19.9%, 42.6% and 
34.6%, respectively. Patients with severe persistent asthma 
had a higher rate of adult onset asthma compared with 
those with moderate persistent and mild intermittent/
persistent disease (69.9% vs 61.6% vs 53.9%, p≤0.001); 
higher smoking rate (10.2% vs 5.3% vs4.3%, p≤0.001); 
HIV- positive status (5.6% vs 2.6% vs 3.5%, p=0.017), 
history of TB (1.9% vs 0.4% vs 1.3%, p=0.032), median 
FeNO (32 vs 22 vs 22, p≤0.001) and median AEC (370 
vs 270 vs 240, p=0.001). Conversely those with severe 
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persistent n (%) P value
n=1649 n=375 n=703 n=571
Short- acting bronchodilators
  Salbutamol tablets/syrup 400 (24.3) 75 (20.0) 198 (28.2) 127 (22.2) 0.005
  Salbutamol inhaler 894 (54.2) 186 (49.6) 347 (49.4) 361 (63.2) <0.001
  Salbutamol/ipratropium 9 (0.5)
  Nebulised salbutamol 169 (10.1) 32 (8.5) 59 (8.4) 78 (13.7) 0.005
  Nebulised salbutamol/ipratropium 33 (2.0) 8 (2.1) 14 (2.0) 11 (1.9) 0.963
Corticosteroids
  Nebulised steroids 26 (1.6) 2 (0.5) 13 (1.9) 11 (1.9) 0.192
  Oral steroids 621 (37.7) 126 (33.6) 280 (39.8) 215 (37.7) 0.185
  Injectable steroids 191 (11.6) 29 (7.7) 92 (13.1) 70 (12.3) 0.033
  Inhaled steroids 230 (14.0) 65 (17.3) 89 (12.7) 76 (13.3) 0.069
Combination inhalers (corticosteroids–long- 
acting beta agonists)
  Combination inhalers 274 (16.6) 56 (14.9) 113 (16.1) 105 (18.4) 0.394
Leukotriene modifiers
  Leukotriene modifiers 128 (7.8) 39 (10.4) 57 (8.1) 32 (5.6) 0.018
Other
  Theophylline/aminophylline tablets 284 (17.2) 40 (10.7) 120 (17.1) 124 (21.7) <0.001
  Theophylline/aminophylline injections 219 (13.3) 30 (8.0) 94 (13.4) 95 (16.6) 0.001
  No current asthma medication 206 (12.5) 73 (19.5) 87 (12.6) 46 (8.1) <0.001
Data presented as count (percentage).
Figure 1 Venn diagram showing overlap between high 
AEC, high FeNo and ≥1 positive SPT in patients with 
all three variables measured (n=1275). Of note, 8.9% of 
the patients did not demonstrate positivity on any of the 
variables. AEC, absoluteeosinophil count; FeNO, fractional 
exhaled nitric oxide; SPT, skinprick test.
persistent asthma had lower rates of GERD compared 
with moderate persistent and mild intermittent/persis-
tent patients (15.2% vs 20.3% vs 15.5%, p=0.030), rhinosi-
nusitis (16.3% vs 24.8% vs 27.5%, p≤0.001) and SPT 
positivity (63.1% vs 69.9% vs 69.9%, p=0.029) (table 2). 
In a multivariate model including these characteristics, 
current use of ICS and country, the only characteristics 
that remained significantly associated with moderate to 
severe persistent asthma were being from the Ethiopian 
site- adjusted OR (95% CI) 4.58 (2.46–8.51, p≤0.001), 
GERD 1.78 (1.20–2.65, p=0.004) and current use of ICS 
0.57 (0.38–0.86, 0.008) (table 4).
DISCuSSIon
The ASAP cohort provides a unique opportunity to under-
stand both the prevalence and characteristics of severe 
asthma in Eastern Africa. Little is known about asthma 
in Africa despite the high morbidity and mortality associ-
ated with this disease. The study enrolled a large number 
of patients and successfully completed phenotypic char-
acterisation in a resource limited setting. Several impor-
tant differences between asthma in this cohort and others 
around the world were identified. The ASAP cohort had 
a higher rate of adult onset asthma patients (62.8%) as 
compared with 24% of a cohort in the Netherlands.22 
Factors that increase the risk of adult onset asthma 
include female gender, obesity, occupational exposures, 
exposure to cleaning agents, air pollution, smoking and 
respiratory infections.25–27 We postulate that the higher 
prevalence of adult onset asthma in this cohort may be 
related to environmental exposures with a large propor-
tion of the patients being exposed to indoor and outdoor 
air pollution. We also recognise that delays in the initial 
G








pen Resp Res: first published as 10.1136/bmjresp-2019-000484 on 12 February 2020. Downloaded from 
Kirenga B, et al. BMJ Open Resp Res 2020;7:e000484. doi:10.1136/bmjresp-2019-000484 7
Open access
Table 4 Association between moderate–severe persistent asthma and selected phenotypic characteristics at multivariate 
analysis
Factor
Unadjusted estimates Adjusted estimates
OR
(95% CI) P value
OR
(95% CI) P value
Country
Uganda Reference Reference
Kenya 1.15 (0.88 to 1.50) 0.305 1.04 (0.72 to 1.49) 0.842
Ethiopia 4.04 (2.78 to 5.87) <0.001 4.58 (2.46 to 8.51) <0.001
Adult onset asthma (onset >19 years) 1.65 (1.30 to 2.10) <0.001 1.24 (0.92 to 1.67) 0.162
Family history of asthma 0.80 (0.63 to 1.01) 0.058 0.95 (0.71 to 1.26) 0.702
Smoking (current/former) 1.81 (1.05 to 3.11) 0.033
Biomass exposure 1.05 (0.81 to 1.36) 0.733 1.02 (0.74 to 1.41) 0.702
HIV 1.14 (0.61 to 2.12) 0.684
Tuberculosis history 0.82 (0.29 to 2.30) 0.709
Hypertension 1.43 (0.97 to 2.11) 0.072
Obesity 1.05 (0.78 to 1.40) 0.767 1.12 (0.78 to 1.61) 0.533
GERD 1.20 (0.88 to 1.65) 0.247 1.78 (1.20 to 2.65) 0.004
Rhinosinusitis 0.70 (0.54 to 0.91) 0.008
At least one positive SPT, % 0.86 (0.67 to 1.10) 0.220
FeNO ≥35 ppb, % 1.37 (1.04 to 1.79) 0.024 1.17 (0.85 to 1.60) 0.329
AEC>300 cells/μL, % 1.45 (1.13 to 1.84) 0.003 1.09 (0.81 to 1.46) 0.571
AEC, absolute eosinophil count; FeNO, fractional exhaled nitric oxide; GERD, gastro- oesophageal disease; SPT, skin prick test.
diagnosis of asthma due to poor access to medical care 
may contribute to a falsely elevated incidence of adult 
onset asthma. Notably, the prevalence of obesity in this 
cohort was very low which is in sharp contrast to most 
adult onset asthma cohorts, therefore obesity is not likely 
to explain the higher prevalence of adult onset asthma 
noted in the ASAP cohort.28–30
The majority of the patients in the cohort had 
moderate and severe persistent asthma with a high level 
of poor asthma control and significant morbidity asso-
ciated with increased healthcare utilisation. The cohort 
was recruited from three tertiary care centres and there-
fore this sample may not be representative of the rates 
of severe disease in the general population. Compara-
tively, a European Community Respiratory Health Survey 
found intermittent, mild persistent, moderate persistent 
and severe persistent asthma rates of 31.7%, 13.5%, 14% 
and 40.7%, respectively.31 These rates are significantly 
lower than those in our cohort. Notably, since the use 
of medications for asthma was very low in our cohort we 
had the opportunity to determine severity in the absence 
of confounding therapies as recommended by the EPR 
3 guidelines which is a strength of this study.32 In addi-
tion, it is not suprising that we found higher severity 
rates, since few patients were using controller medica-
tions; therefore, severe forms of asthma observed could 
be categorised as severe untreated asthma33 rather than 
treatment- resistant asthma which occurs when adequate 
controller therapy has been used.34 We cannot however 
discount the possibility that the prevalence of more severe 
disease is a result of other factors such as race given the 
high prevalence of severe asthma in blacks of African 
descent in other countries.35 Patients in this study had 
high rates of asthma exacerbations with 59.1% reporting 
≥3 exacerbations in the past year. The rates of exacerba-
tions observed are much higher than observed in devel-
oped countries, most likely resulting from untreated or 
undertreated disease. The factors associated with severe 
asthma include tobacco use, HIV, a history of TB, GERD, 
rhinosinusitis, elevated FeNO, AEC and allergic sensitisa-
tion. Use of ICS was associated with a lower odd ratio of 
having severe asthma. Interestingly, although inflamma-
tory markers were more prevalent in severe asthma, the 
impact of these markers on asthma severity was not signif-
icant in our multivariate models. Patients from Ethiopia 
had a higher OR of having severe disease.
Adult onset asthma is associated with a high prevalence 
of allergic and eosinophilic inflammation. We demon-
strate similar findings with a high prevalence of allergic 
and eosinophilic inflammation that is notably most 
prominent in severe asthma which was associated with 
elevated eosinophils and FeNO levels. Interestingly, the 
prevalence of HIV and the presence of parasitic infec-
tion was very low in this cohort, thus ensuring that these 
potential confounders of eosinophilia did not impact the 
high prevalence rates noted in the cohort.36 The high 
rates of allergic sensitisation may be a result of geograph-
ical location, as the study sites were in large urban areas 
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where exposure to allergens is higher. Rates of allergy 
and asthma are known to be higher in urban areas.4
There was discordance between the high prevalence 
of severe disease and the use of maintenance therapies 
for asthma. Significant disparities exist in asthma care 
in the region with a very small proportion of patients 
receiving therapy with ICS and anti- inflammatory combi-
nation therapies. Most of the patients received bron-
chodilator therapy and systemic corticosteroids (SCS) 
which are likely the most economically attainable medi-
cations for asthma. None of the patients were treated 
with biologicals or targeted therapies for asthma. The 
GINA strategy 2019 demonstrated the urgent need for 
a paradigm shift in the management of asthma with a 
particular focus on the negative consequences of short- 
acting beta agonist (SABA) monotherapy in asthma.8 
The patients in our cohort are at an unacceptably high 
risk of the poor outcomes including death that are asso-
ciated with overuse of SABA. More importantly, the toxic-
ities associated with SCS use cannot be understated37 and 
the long- term consequences and economic burden of 
non- communicable diseases that occur at a high rate in 
patients exposed to SCS will be significant.
Our study had limitations including the lack of sputum 
cell counts, specific IgE to determine allergic sensitisa-
tion and total IgE measurements. Blood eosinophils are 
increasingly accepted as surrogate markers of inflamma-
tion in asthma and they accurately identify responders 
to targeted therapies38–41 and were therefore selected for 
this study. Furthermore, sputum is challenging to obtain 
and is not easily generalisable to non- academic settings, 
thus our focus is on blood eosinophils. Other limitations 
of the study are the study being tertiary hospital based 
which could mean that patients recruited may not repre-
sent general population patients, and using African 
American spirometry reference ranges which may not be 
appropriate for East African Americans.
The ASAP study highlights the disparities that exist 
in asthma care in Africa. Despite a high prevalence of 
patients with severe asthma and the associated significant 
morbidity caused by the disease, access to medications is 
limited. This highlights the urgent need for intervention 
and new strategies that can close the gap and improve the 
lives of many patients with asthma. As the focus of interna-
tional organisations moves towards non- communicable 
diseases, the burden of respiratory disease such as asthma 
must be highlighted and addressed.
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